Company profile: Xycrobe
1.1 - Company Overview
Company description
- Provider of early-stage biotechnology research and development leveraging extensive human microbiome data to develop novel therapies for clinical applications, with innovations that utilize microbes as delivery vehicles.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xycrobe
Adaptive Phage Therapeutics
HQ: United States
Website
- Description: Provider of phage-based therapeutic services for multi-drug resistant pathogenic bacteria, using clinical technology to match phages to patient-specific infections; offerings include BX004 for cystic fibrosis Pseudomonas aeruginosa, BX211 for diabetic foot osteomyelitis, personalized and optimized phage therapies, and the XMarker platform for microbial biomarker discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptive Phage Therapeutics company profile →
Seres Therapeutics
HQ: United States
Website
- Description: Provider of microbiome therapeutics, including VOWST, an FDA-approved oral microbiota-based therapy to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment; SER-155, an investigational oral microbiome therapeutic aimed at reducing gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients; and a platform to design, test, and manufacture bacterial consortia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seres Therapeutics company profile →
Solarea Bio
HQ: United States
Website
- Description: Provider of microbial therapeutics and microbial-based solutions targeting chronic inflammation. Develops Defined Microbial Assemblage products combining probiotic microbes from fruits and vegetables with prebiotic fibers, advances medical foods, and creates synbiotics to protect against bone loss. Also offers licensing of its microbial-based technology, including a technology licensing agreement with ADM.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Solarea Bio company profile →
Biocontrol
HQ: United Kingdom
Website
- Description: Provider of a novel system using biological agents to control bacterial infections by Pseudomonas aeruginosa, with proven efficacy and safety even where conventional antibiotics have failed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocontrol company profile →
Infinant Health
HQ: United States
Website
- Description: Provider of infant gut microbiome solutions, offering Evivo Powder, a daily supplement for infants fed any amount of breast milk to establish a protective gut microbiome and support healthy immune function, and B. infantis EVC001, a bacterial strain discovered by Infinant Health and proven pivotal to infant immune health, particularly when combined with breast milk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infinant Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xycrobe
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xycrobe
2.2 - Growth funds investing in similar companies to Xycrobe
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xycrobe
4.2 - Public trading comparable groups for Xycrobe
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →